Malley Thomas 4

What Happened

• Thomas Malley, a director of Kura Oncology (KURA), was granted a derivative award on 2026-06-04 representing 35,000 shares. The Form 4 records the acquisition amount as $0.00, indicating an equity award/option rather than an open-market purchase or sale. Per the filing footnote, the option vests in full on the one-year anniversary of the grant.

Key Details

• Transaction date: 2026-06-04; Form filed: 2026-06-04 (filed same day).
• Transaction type: Award/Grant (derivative security) for 35,000 shares; reported price $0.00 on Form 4.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnote: "This option vests in full on the one year anniversary of the date of grant."
• Timeliness: Filing date matches transaction date (no late filing indicated from provided data).

Context

• This was an equity award (option/derivative), not an immediate cash purchase or sale. Such grants are commonly used for director compensation and carry vesting and exercise terms; they do not necessarily reflect immediate buying/selling sentiment. The filing does not disclose exercise price or other exercise terms in the provided excerpt.